UCLA-led research on telomerase could lead to new strategies for treating disease
An enzyme called telomerase plays a significant role in aging and most cancers, but until recently many aspects of the enzyme’s structure could not be clearly seen.
Now, scientists from UCLA and UC Berkeley have produced images of telomerase in much higher resolution than ever before, giving them major new insights about the enzyme. Their findings, published online today by the journal Science, could ultimately lead to new directions for treating cancer and preventing premature aging.
“Many details we could only guess at before, we can now see unambiguously, and we now have an understanding of where the different components of telomerase interact,” said Juli Feigon, a professor of chemistry and biochemistry in the UCLA College and a senior author of the study. “If telomerase were a cat, before we could see its general outline and the location of the limbs, but now we can see the eyes, the whiskers, the tail and the toes.”
The research brought together experts in structural biology, biochemistry and biophysics, and a wide range of cutting-edge research techniques.
Telomerase’s primary job is to maintain the DNA in telomeres, the structures at the ends of our chromosomes that act like the plastic tips at the ends of shoelaces. When telomerase isn’t active, each time our cells divide, the telomeres get shorter. When that happens, the telomeres eventually become so short that the cells stop dividing or die.
On the other hand, cells with abnormally active telomerase can constantly rebuild their protective chromosomal caps and become immortal. Making cells immortal might sound like a promising prospect, but it actually is harmful because DNA errors accumulate over time, which damages cells, said Feigon, who also is a researcher at UCLA’s Molecular Biology Institute and an associate member of the UCLA–Department of Energy Institute of Genomics and Proteomics.
Telomerase is particularly active in cancer cells, which helps make them immortal and enables cancer to grow and spread. Scientists believe that controlling the length of telomeres in cancer cells could be a way to prevent them from multiplying.
When Feigon began her research on telomerase slightly more than a decade ago, she merely wanted to learn how telomerase works; fighting cancer and slowing the aging process were not even in the back of her mind.
“Our research may make those things achievable, even though they were not our goals,” she said. “You never know where basic research will go. When telomerase and telomeres were discovered, no one had any idea what the impact of that research would be. The question was, ‘How are the ends of our chromosomes maintained?’ We knew there had to be some activity in the cell that does that.”
Earlier research led by UC San Francisco professor Elizabeth Blackburn revealed that telomerase was responsible for this activity, but the study didn’t connect telomerase to cancer and it provided little information about its structural biology. The research was conducted using tiny, single-celled microorganisms called Tetrahymena thermophila that are commonly found in freshwater ponds. Blackburn won a Nobel Prize in 2009 for the finding.
Since then, Feigon and her colleagues have been filling in pieces of the telomerase puzzle, also using Tetrahymena. Their latest study found that the microorganism’s telomerase is more analogous to human telomerase than previously thought.
“This is the first time that a whole telomerase directly isolated from its natural workplace has been visualized at a sub-nanometer resolution and all components are identified in the structure,” said Jiansen Jiang, the study’s co-lead author and a UCLA postdoctoral scholar. (A nanometer is equivalent to one billionth of a meter.)
Among the new insights the team reported:
- Scientists had thought telomerase contains eight sub-units: seven proteins and an RNA. But Feigon and her colleagues discovered two additional proteins, Teb2 and Teb3, that increase telomerase’s activity. “Knowing we were the first people in the world who knew about these new proteins was amazing,” she said. “Days like that are what scientific discovery is all about, and it’s exhilarating.”
- Feigon’s research team knew that the RNA strand interacts with the proteins, but not exactly where it interacted. The new study found that within the enzyme’s “catalytic core,” which is formed by the RNA and its partner proteins TERT and p65, the RNA forms a ring around the donut-shaped TERT protein.
- Scientists previously knew that telomerase contains three proteins, p75, p45 and p19, but their structures and functions were poorly understood. The new research identified the proteins’ structures and revealed that they are similar to proteins found at human telomeres.
- The researchers showed that a key protein called p50 interacts with several components of telomerase, including TERT, Teb1 and p75, and this network of interactions has important implications for telomerase’s function.
Feigon knew that the Tetrahymena enzyme’s catalytic core, where the majority of the telomerase activity occurs, was a close analogue to the catalytic core in the human enzyme, but she did not previously know whether the other proteins had human counterparts.
“It turns out that nearly all, if not all, of the telomerase proteins in Tetrahymena have similar proteins in humans,” Feigon said. “Now we can use our model system to learn more about how telomerase interacts at the telomeres.”
Feigon and her colleagues are working to fill in even more details of the telomerase puzzle. Their research could lead to the development of pharmaceuticals that target specific sub-units of telomerase and disrupt interactions between proteins.
“There is so much potential for treating disease if we understand deeply how telomerase works,” Feigon said.
Read more: Scientists produce clearest-ever images of enzyme that plays key roles in aging, cancer
The Latest on: Telomerase
via Google News
The Latest on: Telomerase
- Geron to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conferenceon August 3, 2022 at 3:30 pm
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies.
- MAIA Biotechnology Receives FDA Orphan Drug Designation for THIO for the Treatment of Small-Cell Lung Cancer (SCLC)on August 2, 2022 at 5:00 am
MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that ...
- Creative Bioarray Has Developed Cell Immortalization Services to Support Potential Drug Developmenton August 1, 2022 at 5:00 pm
Creative Bioarray, one of the leading biotechnology companies focuses on developing high-quality products and services in order to accelerate research in the field of biopharma, drug development and ...
- MAIA Biotechnology Announces Closing of Initial Public Offeringon August 1, 2022 at 12:30 pm
MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the closing of its ...
- This doctor reversed heart disease. Now he wants to do it for Alzheimer'son August 1, 2022 at 7:53 am
In 1990, internal medicine specialist Dr. Dean Ornish did what no other doctor had been able to do: He published results of a randomized clinical trial that used advanced imagery ...
- Build your health & fitness knowledgeon August 1, 2022 at 5:30 am
Dr. Dean Ornish is trying to do for the brain what he did for the heart. At his nonprofit Preventive Medicine Research Institutein California, he's using the same four lifestyle ...
- Be the first to knowon August 1, 2022 at 5:30 am
Dr. Dean Ornish is trying to do for the brain what he did for the heart. At his nonprofit Preventive Medicine Research Institutein California, he's using the same four lifestyle ...
- STEMON: REGISTRATION OF TELOMERE RESTORING EXOSOME “TELOMERE REPROSOME” IN ICID.on July 27, 2022 at 8:01 pm
The newly registered substance is TELOMERE REPROSOME, a customized exosome capable of telomere length restoration and regeneration, and is manufactured to induce exosomes containing telomerase (TERT) ...
- STEMON: Registration of Telomere Restoring Exosome “Telomere Reprosome” in ICIDon July 26, 2022 at 10:30 am
Registration of telomere length restoration as raw material ingredients in the world’s first International Cosmetics Raw Material Collection (ICID). Bio-venture company, STEMON, [(CEO Soonhag ...
- Telomerase and cancer therapeuticson April 30, 2021 at 5:59 am
Telomerase is an important drug target for cancer. It is expressed in most tumours from virtually all types of cancers and is required for long-term maintenance of telomeres, which in turn is ...
via Bing News